DailyIQ
|
Sector:HealthcareAll sectors
Last updated 10 minutes ago

NVO·Novo Nordisk A/S

$.
+. (+.%)
After Hours
High
$45.23
Open
$44.17
Market Cap
1284.32B
52W High
$533.40
Low
$44.05
P. Close
$44.55
P/E
10.53
52W Low
$224.25
Fwd P/E
8.59
Mean Target
$46.76
Technical Score (1D)
59
BUY
News Sentiment
77
BULLISH
Novo Nordisk is set to present new data from its cardiometabolic pipeline at the American Diabetes Association's 2026 Scientific Sessions, including Phase 3 results for CagriSema and mid-stage data for zenagamtide. New semaglutide data will also highlight its cardiometabolic profile. This focus on advancing its pipeline comes as the POSEIDON study revealed a significant residual inflammatory risk in treated heart disease patients, underscoring an unmet medical need that aligns with Novo Nordisk's strategic direction. In other developments, Brazil has approved the first generic version of Ozempic, introducing increased competition for the blockbuster drug in that market. Separately, the European Union is considering label expansions for Novo Nordisk's GLP-1 drugs, which could broaden patient access and drive significant sales growth if approved. To support its valuation, Novo Nordisk has also launched a substantial share repurchase program, aiming to buy back B shares valued up to DKK 11.2 billion through February 2027. Traders should monitor the market penetration of the Ozempic generic in Brazil and the outcomes of the EU's regulatory decisions on label expansions.
Earnings Summary
Novo Nordisk A/S is a global pharmaceutical company focused on diabetes, obesity, and rare disease treatments, operating within the Healthcare sector's Drug Manufacturers - General industry. The company develops, manufactures, and distributes a range of medications, including smart diabetes solutions, and is structured around two main segments: Diabetes and Obesity Care, and Rare Disease. In its most recent reported quarters, NVO demonstrated mixed performance against analyst expectations. For Q2 2025, the company reported actual EPS of $5.96, missing the estimate of $6.00433, while revenue actuals were not provided. This followed a Q1 2025 where actual EPS was $6.53, beating the estimate of $6.074, with actual revenue reported at $78.087 billion. Prior to this, Q4 2024 saw actual EPS of $6.34 against an estimate of $6.115, and Q3 2025 reported actual EPS of $4.50, exceeding the estimate of $4.24333. The company has shown a pattern of beating EPS estimates in three of the last four reported quarters, with revenue data only available for Q1 2025 and Q4 2024, where actual revenue was $85.683 billion. Looking ahead, investors will be watching for NVO's performance in Q1 2026 and Q2 2026, with analyst estimates for EPS at $6.96067 and $5.17233 respectively, and revenue estimates at $71.56 billion and $73.01 billion. Recent news highlights a significant development with the European Medicines Agency's positive opinion on the oral version of Wegovy, a key indicator for the company's expanding GLP-1 portfolio in obesity care. This regulatory step, alongside a partnership with Hims & Hers Health, suggests potential growth drivers, though competition in the GLP-1 market remains a factor to monitor.

EPS

EstBeatMiss
$3.84$4.72$5.60$6.49$7.37Q4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$6.96 - -
Q3'25$4.24$4.50+6.0%
Q2'25$6.00$5.96-0.7%
Q1'25$6.07$6.53+7.5%
Q4'24$6.12$6.34+3.7%

Revenue

EstBeatMiss
$69.4B$74.0B$78.6B$83.2B$87.8BQ4'24Q1'25Q2'25Q3'25Q1'26
QtrEstActual+/−
Q1'26$71.6B - -
Q3'25 - $75.0B -
Q2'25 - $76.9B -
Q1'25 - $78.1B -
Q4'24 - $85.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

NVO Stock Snapshot

NVO is currently trading at $44.56, giving Novo Nordisk A/S a market cap of 1284.32B and a P/E ratio of 10.5. Today's range spans $44.05–$45.23, with shares opening at $44.17 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 77/100.

Over the past year NVO has traded between $224.25 and $533.40 - the current price is -80.1% off the 52-week low and -91.6% from the high. 37 analysts cover the stock with a Hold consensus and a mean 12-month target of $46.76 (range $39.56–$64.19), implying upside of +4.9%.

For NVO - mega-cap, Healthcare, 1284.32B market cap - the HOLD signal (59/100) at $44.56 (near 52-week lows) reflects a market absorbing prior gains rather than reversing them. Sentiment at bullish (77/100) doesn't give bulls or bears an edge. The current P/E ratio stands at 10.5. In the 52-week context of $224.25–$533.40, a neutral phase at this level is where positioning gets cleaned up before the next directional trade is viable.

In a HOLD phase, the key question for NVO is what breaks the equilibrium: a macro shift, an earnings revision, or a sector catalyst. At 1284.32B in Healthcare capitalization, the 59/100 reading (HOLD) and bullish sentiment (77/100) describe a market that's watching rather than acting — and $44.56 (near 52-week lows) sits in the zone where both buyers and sellers are willing to wait for confirmation.